Obesity rates in the UK propel NHS prescription expenditure beyond £10 billion
As obesity rates continue to escalate in the UK, National Health Service (NHS) officials report that the annual expenditure on prescription medication has crossed the £10 billion mark.
During the financial year of 2022/23, the NHS allocated £10.4 billion to prescription drugs, which is an approximately 10% increase compared to the preceding year.
A pivotal factor contributing to this surge in spending is the sharp rise in prescriptions for type 2 diabetes medications, such as dapagliflozin and metformin. The NHS spent an estimated £1.4 billion on these medications alone, as per the new report.
Currently, over 60% of the population in the UK is considered overweight, and this figure is expected to climb in the foreseeable future.
In response to the burgeoning obesity crisis, the UK Government plans to provide the weight loss injection semaglutide to individuals struggling with obesity. The medication, branded as Ozempic and Wegovy, is presently available through the NHS for certain patients diagnosed with type 2 diabetes. Last year, the drug accounted for nearly £107 million of the NHS’s expenditure, making it the 11th most costly prescription medication.
The report also highlighted that the anticoagulant Apixaban, used to prevent blood clots, topped the list as the most expensive drug, costing the NHS over £400 million.
Tam Fry of the National Obesity Forum lamented the fact that little had been done over the past 25 years to prevent obesity. “We are now faced with a staggering number of individuals who require medication to shed weight. Failing to prevent the condition means we are inevitably burdened with exorbitant costs to address it,” he stated.
Fry criticised the NHS for incurring high treatment expenses, stressing that preventative measures are invariably more cost-effective. “Starting from infancy, proactive measures are imperative. It is deeply frustrating to witness the government’s inertia,” he added.
He asserted that prioritising the prevention of obesity, especially during the first five years of life, could save the NHS a substantial amount of money in the long run.
Recent studies reveal that 10% of children have obesity by the time they enter primary school, with this figure rising to one in five by year six. Individuals with obesity are at a heightened risk of developing various health issues, including type 2 diabetes, certain cancers, and cardiovascular diseases.
In response to the criticisms, a Government spokesperson defended their efforts to combat obesity. “We have implemented various strategies, including restrictions on the placement of unhealthy foods in supermarkets, menu calorie labelling, and collaborative initiatives with the industry to promote healthier food options,” they stated.
The spokesperson also highlighted the success of the voluntary sugar reduction program in significantly decreasing the sugar content in children’s foods. They credited the sugar tax with halving the amount of sugar in soft drinks.
John O’Connell, Chief Executive of the TaxPayers’ Alliance, expressed concerns over the financial burden on taxpayers. “The public is undoubtedly exasperated with bearing these costs, especially when cheaper alternatives are available over the counter,” he remarked.
He urged NHS authorities to take decisive measures to curtail the issue, adding, “The evident ineffectiveness of the existing ban necessitates further action to mitigate these relentless prescriptions.”
